NASDAQ: SPRY
Ars Pharmaceuticals Inc Stock Ownership - Who owns Ars Pharmaceuticals?

Insider buying vs selling

Have Ars Pharmaceuticals Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Brian DorseyChief Operating Officer2025-11-1321,828$0.64
$13.97kBuy
Brian DorseyChief Operating Officer2025-11-1321,828$8.71
$190.06kSell
Justin ChakmaChief Business Officer2025-11-1230,000$0.84
$25.20kBuy
Justin ChakmaChief Business Officer2025-11-1230,000$8.91
$267.36kSell
Justin ChakmaChief Business Officer2025-11-12136,380$8.86
$1.21MSell
Kathleen D. ScottChief Financial Officer2025-08-2112,500$1.50
$18.75kBuy
Kathleen D. ScottChief Financial Officer2025-08-2112,500$15.00
$187.50kSell
Richard E. LowenthalPRESIDENT AND CEO2025-08-2150,000$14.49
$724.35kSell
Sarina TanimotoCHIEF MEDICAL OFFICER2025-08-2037,656$14.09
$530.61kSell
Sarina TanimotoCHIEF MEDICAL OFFICER2025-08-1912,344$14.03
$173.12kSell

1 of 3

SPRY insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when SPRY insiders and whales buy or sell their stock.

SPRY Shareholders

What type of owners hold Ars Pharmaceuticals Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Richard E. Lowenthal22.11%21,952,529$181.11MInsider
Sarina Tanimoto20.50%20,360,336$167.97MInsider
Orbimed Advisors LLC17.15%17,029,398$140.49MInsider
Peter A. Thompson17.15%17,029,398$140.49MInsider
Ra Capital Management LP10.94%10,860,977$89.60MInstitution
James E. Flynn9.84%9,774,508$80.64MInsider
Orbimed Advisors LLC8.35%8,288,510$68.38MInstitution
Deerfield Management Company LP7.56%7,503,812$61.91MInstitution
Rubric Capital Management LP6.24%6,200,000$51.15MInstitution
Blackrock Inc5.12%5,085,317$41.95MInstitution

1 of 3

SPRY vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
SPRY45.97%54.03%Net Selling
ABUS30.49%69.51%
MPLT45.71%54.29%Net BuyingNet Selling
SANA52.89%47.11%Net SellingNet Selling
EVMN56.26%43.74%Net BuyingNet Buying

Ars Pharmaceuticals Stock Ownership FAQ

Who owns Ars Pharmaceuticals?

Ars Pharmaceuticals (NASDAQ: SPRY) is owned by 89.61% institutional shareholders, 105.33% Ars Pharmaceuticals insiders, and 0.00% retail investors. Richard E. Lowenthal is the largest individual Ars Pharmaceuticals shareholder, owning 21.95M shares representing 22.11% of the company. Richard E. Lowenthal's Ars Pharmaceuticals shares are currently valued at $179.35M.

If you're new to stock investing, here's how to buy Ars Pharmaceuticals stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.